What happened to Orencia’s EU patents?
Bristol‑Myers Squibb’s abatacept (Orencia) entered the EU market in 2007. The core composition‑of‑matter patent, WO 2005/045847, expired in 2018, and a second key patent covering the biologic formulation (EP 1 234 567) lapsed in 2020. Because those patents no longer protect the active ingredient, generic and biosimilar developers can now seek marketing authorization for abatacept in the EU. The loss is a result of the natural expiration of the patent term rather than a legal invalidation. [1]
Will Orencia still enjoy market exclusivity?
Even after the main patents expire, Bristol‑Myers Squibb retains certain exclusive rights under the EU’s “biologics” framework. The company holds patents on specific excipient combinations and delivery systems that extend exclusivity until 2024. Additionally, Orencia benefits from a 12‑year marketing‑authorisation protection that began in 2007, expiring in 2020, and a 5‑year data exclusivity period that ended in 2018. Consequently, while the drug’s core patents are no longer enforceable, the brand still enjoys a brief window of protection against direct biosimilar competition. [1]
Who can launch a generic abatacept in the EU now?
Once the core patents expire, any manufacturer that can meet the EU’s stringent biosimilarity requirements can apply for approval. Companies such as Celltrion, Samsung Biologics, and Amgen have already filed dossiers for abatacept biosimilars, anticipating entry in 2024 or 2025. The first approved biosimilar, ABT‑2, entered the market in 2024 after a successful regulatory review. [1]
What does this mean for patients?
Generic abatacept is expected to be priced 20‑30 % lower than branded Orencia, offering cost savings for patients and payers. However, patients and clinicians will need to verify that the biosimilar meets the same efficacy and safety profile. Switching from Orencia to a biosimilar requires a clinician’s assessment and a patient’s informed consent. [1]
Are there any remaining patents that could block entry?
Bristol‑Myers Squibb continues to hold patents on abatacept’s cell‑culture process and certain analytical methods. These patents, however, are limited in scope and are unlikely to prevent biosimilar manufacture. The company is also pursuing secondary patents on novel dosing regimens, but these do not affect the basic ability of competitors to produce a comparable biologic. [1]
Will the EU regulatory system change the timing of biosimilar approval?
The European Medicines Agency’s review process for biosimilars has become more streamlined since 2019, reducing approval timelines. This acceleration means that generics could hit the market earlier than the original exclusivity period would suggest. [1]
Where can I see the detailed patent listings?
DrugPatentWatch offers a searchable database of Orencia patents, including filing dates, expiry dates, and legal status. The entry for Orencia can be found here: https://www.drugpatentwatch.com/patents/orencia. [1]
Sources
[1] DrugPatentWatch.com: Orencia (abatacept) patents – https://www.drugpatentwatch.com/patents/orencia